GUIAS HIPERTENSION ARTERIAL.indb - Scc

292
GUÍAS COLOMBIANAS PARA EL DIAGNÓSTICO
Y TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL
4. Van de Werf F, Ardissino D, Betriu A, et al. Task force on the management of acute
myocardial infarction of the European Society of Cardiology. Management of
acute myocardial infarction in patients presenting with ST-segment elevation. The
Task Force on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Eur Heart J 2003; 24: 28-66.
5. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive
drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl
J Med 1996; 335: 1660-1667.
6. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists´
Collaboration. Effects of ACE inhibitors, calcium antagonists, and other
blood-pressure-lowering drugs: results of prospectively designed overviews of
randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Lancet 2000; 356: 1955-1964.
7. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised
trial of intravenous atenolol among 16 027 cases of suspected acute
myocardial infarction: ISIS-1. Lancet 1986; 2: 57-66.
8. The MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction
(MIAMI): a randomised placebo-controlled international trial. Eur Heart J 1985;
6: 199-226.
9. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade
following thrombolytic therapy in patients with acute myocardial infarction.
Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation
1991; 83: 422-437.
10. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after
myocardial infarction: an overview of the randomized trials. Prog Cardiovasc
Dis 1985; 27: 335-371.
11. Harjai KJ, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on
clinical outcomes after primary coronary angioplasty for acute myocardial
infarction. Am J Cardiol 2003; 91: 655–660.
12. Halkin A, Nikolsky E, Aymong E, et al. The survival benefit of periprocedural
beta-blockers in patients with acute myocardial infarction undergoing primary
angioplasty is determined by use of these drugs before admission. Am J Cardiol
2003; 92 (suppl. L): 228L.
13. Kernis SJ, Arguya KJ, Boura J, et al. Does beta-blocker therapy improve clinical
outcomes of acute myocardial infarction after successful primary angioplasty? A
pooled analysis from the primary angioplasty in myocardial infarction-2 (PAMI-2),
no surgery on-site (noSOS), stent PAMI and Air PAMI trials. Circulation 2003;
108 (suppl. IV): 416-417.
14. Lopez-Sendon J, Swedberg K, McMurray J, et al. Task Force on Beta-blockers
of the European Society of Cardiology. Expert consensus document on betaadrenergic
receptor blockers. Eur Heart J 2004; 25: 1341-1362.
15. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality
and reinfarction in patients surviving acute myocardial infarction. N Engl J Med
1981; 304: 801-807.
16. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol
in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;
247: 1707-1714.
17. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after
myocardial infarction: systematic review and meta regression analysis. BMJ
1999; 318: 1730-1737.
18. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise
choice? Lancet 2004; 364: 1684-1689.
19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive
treatment in older persons with isolated systolic hypertension. Final results of
the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:
3255-3264.
20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial infarction.
Results of the survival and ventricular enlargement trial. The SAVE Investigators.
N Engl J Med 1992; 327: 669-677.
21. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril
on mortality and morbidity of survivors of acute myocardial infarction with clinical
evidence of heart failure. Lancet 1993; 342: 821-828.
22. Viscoli CH, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction:
influence of first-year clinical course on long-term effectiveness. Ann Intern Med
1993; 118: 99-105.
23. Hunt SA, for the Task Force on Practice Guidelines (Committee to Revise the
1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA
Guidelines for the Evaluation and Management of Chronic Heart Failure in the
Adult. Disponible en: http://www.acc.org/clinical/guidelines/failure/
Revista Colombiana de Cardiología
Febrero 2007
24. Van de Werf, Ardissino D, Betriu A, et al. Task Force on the management of acute
myocardial infarction of the European Society of Cardiology. Management of
acute myocardial infarction in patients presenting with ST-segment elevation. The
Task Force on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Eur Heart J 2003; 24: 28-66.
25. Report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Management of Acute Myocardial
Infarction) ACC/AHA Guidelines for the Management of Patients With Acute
Myocardial Infarction American College of Cardiology; September 1999. Disponible
en: www.acc.org.
26. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV:
a randomised factorial trial assessing early oral captopril, oral mononitrate
and intravenous magnesium sulphate in 58050 patients with suspected acute
myocardial infarction. Lancet 1995; 345: 669-685.
27. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction
Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensinconverting-enzyme
inhibitor on mortality and morbidity after anterior myocardial
infarction. N Engl J Med 1995; 332: 80-85.
28. Chinese Cardiac Study Collaborative group. Oral captopril versus placebo among
13,634 patients with suspected acute myocardial infarction: interim report from
the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-687.
29. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.
GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together
on 6 week mortality and ventricular function after acute myocardial infarction.
Lancet 1994; 343: 1115-1122.
30. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of
early administration of enalapril on mortality in patients with acute myocardial
infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study
II (CONSESUS II). N Engl J Med 1992; 327: 678-684.
31. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE
inhibitors in the early treatment of acute myocardial infarction: systematic overview
of individual data from 100 000 patients in randomized trials. Circulation
1998; 97: 2202-2212.
32. Gottlieb S, Leor J, Shotan A, et al. Comparison of effectiveness of angiotensinconverting
enzyme inhibitors after acute myocardial infarction in diabetic versus
nondiabetic patients. Am J Cardiol 2003; 92: 1020-1025.
33. Kober L, Torp-Pedersen C, Carlsen JE, et al, for the trandolapril cardiac evaluation
(TRACE) study group. A clinical trial of the angiotensin converting enzyme
inhibitor trandolapril in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med 1995; 33: 1670-1676.
34. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients
with heart failure or left-ventricular dysfunction: a systematic overview of data
from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative
Group. Lancet 2000; 355: 1575-1581.
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl
J Med 2000; 342: 145-153 [Errata, N Engl J Med 2000; 342: 748-1376.]
36. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in
stable coronary Artery disease Investigators. Efficacy on perindopril in reduction
of cardiovascular events among patients with stable coronary artery disease:
randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003; 362: 782-788.
37. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme
inhibition in stable coronary artery disease. N Engl J
Med 2004; 351: 2058-2068.
38. López-Sendón J, Swedberg K, McMurray J, et al. Task Force on ACE-inhibitors
of the European Society of Cardiology. Expert consensus document on angiotensin
converting enzyme inhibitors in cardiovascular disease. The Task Force
on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;
25: 1454-1470.
39. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors,
calcium antagonists, and other blood-pressure-lowering drugs: results
of prospectively designed overviews of randomised trials. Lancet 2000; 355:
1955-1964.
40. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure
reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.
41. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality
in patients with coronary heart disease. Circulation 1995; 92: 1326-31.